TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis
Brief Summary: The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients.


Options:
A: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF
B: Arm Label: Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Laminectomy and bone marrow stem cells transplantation, Procedure: Autologous bone marrow cells collection | Intervention Type: PROCEDURE; Name: Laminectomy and bone marrow stem cells transplantation; Assigned to Arm(s): Transplant | Intervention Type: PROCEDURE; Name: Autologous bone marrow cells collection; Assigned to Arm(s): Transplant
C: Arm Label: MSC-NTF cells IM; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IM) | Arm Label: MSC-NTF cells IT; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IT) | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IM); Assigned to Arm(s): MSC-NTF cells IM | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IT); Assigned to Arm(s): MSC-NTF cells IT
D: Arm Label: Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously; Type: EXPERIMENTAL; Interventions: Biological: Injection of autologous bone marrow derived mesenchymal stem cells | Intervention Type: BIOLOGICAL; Name: Injection of autologous bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis
Brief Summary: The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sclerosis patients.


Options:
A: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF
B: Arm Label: Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Laminectomy and bone marrow stem cells transplantation, Procedure: Autologous bone marrow cells collection | Intervention Type: PROCEDURE; Name: Laminectomy and bone marrow stem cells transplantation; Assigned to Arm(s): Transplant | Intervention Type: PROCEDURE; Name: Autologous bone marrow cells collection; Assigned to Arm(s): Transplant
C: Arm Label: stem cell reciepient; Type: EXPERIMENTAL; Interventions: Biological: intra venous injection of stem cell | Intervention Type: BIOLOGICAL; Name: intra venous injection of stem cell; Assigned to Arm(s): stem cell reciepient
D: Arm Label: Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously; Type: EXPERIMENTAL; Interventions: Biological: Injection of autologous bone marrow derived mesenchymal stem cells | Intervention Type: BIOLOGICAL; Name: Injection of autologous bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-center,Proof of Concept,Randomized,Controlled Parallel Group Clinical Trial of the Effects of Exenatide vs. a Long Acting Insulin Analog to Evaluate the Efficacy of Exenatide in Patients With Diabetic Neuropathy and Type 2 Diabetes
Brief Summary: This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glargine | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): glargine
B: Arm Label: Liraglutid; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
D: Arm Label: Anagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Anagliptin; Assigned to Arm(s): Anagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Brief Summary: The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).


Options:
A: Arm Label: Riociguat (Adempas, BAY63-2521)_individual dose titration; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521)_individual dose titration | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Brief Summary: The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Riociguat (Adempas, BAY63-2521)_individual dose titration; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521)_individual dose titration | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
D: Arm Label: 20 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 40 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 20 mg tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 40 mg tadalafil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Brief Summary: The purpose of this exploratory study is to determine whether memantine can provide benefits on clinical symptoms in patients with Parkinson's Disease Dementia or Dementia with Lewy Bodies.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Device: Gait Trainer 3 | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Gait Trainer 3 | Intervention Type: DEVICE; Name: Gait Trainer 3; Assigned to Arm(s): Control Group, Experimental group
B: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3, Dietary Supplement: calcium | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium, Other: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: Isradipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isradipine | Arm Label: Placebo (for Isradipine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Isradipine) | Intervention Type: DRUG; Name: Isradipine; Assigned to Arm(s): Isradipine | Intervention Type: DRUG; Name: Placebo (for Isradipine); Assigned to Arm(s): Placebo (for Isradipine)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Brief Summary: The purpose of this exploratory study is to determine whether memantine can provide benefits on clinical symptoms in patients with Parkinson's Disease Dementia or Dementia with Lewy Bodies.


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare
Brief Summary: This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.


Options:
A: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rilonacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: crFMF: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: crCMF: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: HIDS/MKD: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: HIDS/MKD: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: TRAPS: 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: TRAPS: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): HIDS/MKD: 150 mg, TRAPS: 150 mg, crFMF: 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): HIDS/MKD: placebo, TRAPS: placebo, crCMF: placebo
D: Arm Label: Placebo (for Rilonacept) and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Other: Placebo (for Rilonacept) | Arm Label: Rilonacept and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Drug: Indomethacin | Arm Label: Rilonacept and Placebo (for Indomethacin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Other: Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): Rilonacept and Indomethacin, Rilonacept and Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin, Rilonacept and Indomethacin | Intervention Type: OTHER; Name: Placebo (for Indomethacin); Assigned to Arm(s): Rilonacept and Placebo (for Indomethacin) | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare
Brief Summary: This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg
B: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
C: Arm Label: Canakinumab; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): Canakinumab
D: Arm Label: Placebo (for Rilonacept) and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Other: Placebo (for Rilonacept) | Arm Label: Rilonacept and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Drug: Indomethacin | Arm Label: Rilonacept and Placebo (for Indomethacin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Other: Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): Rilonacept and Indomethacin, Rilonacept and Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin, Rilonacept and Indomethacin | Intervention Type: OTHER; Name: Placebo (for Indomethacin); Assigned to Arm(s): Rilonacept and Placebo (for Indomethacin) | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Exercise in Promotion Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy
Brief Summary: The objective of the proposed research is to determine the efficacy of a home-based walking exercise program in promoting cognitive-psychosocial functions of men with prostate cancer receiving androgen depletion therapy (ADT). ADT is the mainstay treatment for men with advanced prostate cancer. However, ADT has a number of side effects including compromised cognitive function, depression and anxiety, which negatively impacts the quality of life of men with prostate cancer. The central question of the proposed research is to determine if exercise will have a positive impact on the quality of life of men with prostate cancer undergoing ADT.

Hypothesis:


Options:
A: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
B: Intervention Type: PROCEDURE; Name: Memory Training; Assigned to Arm(s): N/A
C: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes
Brief Summary: The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: add-on pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: add-on sulphonylurea | Intervention Type: DRUG; Name: add-on pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: add-on sulphonylurea; Assigned to Arm(s): 2
B: Arm Label: Metformin + Alogliptin 12.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin, Drug: Metformin | Arm Label: Metformin + Alogliptin 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin, Drug: Metformin | Arm Label: Metformin + Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glipizide | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Metformin + Alogliptin 12.5 mg, Metformin + Alogliptin 25 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin + Alogliptin 12.5 mg, Metformin + Alogliptin 25 mg, Metformin + Glipizide | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): Metformin + Glipizide
C: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin, Drug: Sulphonylruea | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Sulphonylruea; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo

Answer: B